Stockreport

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin Inc. Common Shares  (CYBN) 
PDF - Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (“MDD”) -- Initiated PARADIGM: A Multina [Read more]